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The canonical pathway of thyroid hormone signaling involves its binding to nuclear recep-
tors (TRs) acting directly on the transcription of a number of genes. Recent genome-wide 
studies revealed that chromatin occupancy by TR is not sufficient for transactivation of 
gene expression. Reciprocally, in some cases, DNA binding by TR may not be required 
for cellular response. This leaves many new questions to be addressed in future research.
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A CANONiCAL PATHwAY FOR THYROiD HORMONe SiGNALiNG
In 1986, the genes that encode the TRα1 and TRβ1 nuclear receptors of thyroid hormone (trii-
odothyronine or T3), now called THRA and THRB, were cloned (1–3). This breakthrough started 
years of intense investigations (4), which established what we will call here the canonical T3 signaling 
pathway. The key observations were:
 – THRA and THRB belong to a superfamily of 48 genes present in the mammalian genome, which 
also encode nuclear receptors. The mode of action of these nuclear receptors shares a number of 
common features. Like many other nuclear receptors, T3 receptors (TRs including TRα1, TRβ1, 
and TRβ2 an alternate product of THRB later found in few cell types) act as ligand-dependent 
transcription factors.
 – The structure of TRs is modular: the N-terminal domain binds DNA and is linked by a “hinge” to 
the C-terminal domain, which binds T3 and is required for heterodimers formation. TRα1, TRβ1, 
and TRβ2 display extensive structural similarities, with the exception of an N-terminal extension, 
which is absent in TRα1.
 – Like a subset of other nuclear receptors, TRs act mainly as heterodimers with the RXR nuclear 
receptor. RXR/TR heterodimers can bind to DNA elements made of two half-sites, related to the 
5′-AGGTCA-3′ consensus, organized in tandem and separated by four nucleotides (DR4).
 – DNA binding is not ligand dependent. Unliganded TRs recruit transcription corepressors and 
exert a negative influence on gene expression. T3 binding changes the conformation of the ligand-
binding domain of TRs. According to the “mouse trap” model, the repositioning the C-terminal 
helix 12 favors the recruitment of transcription coactivators at the expense of transcription 
corepressors. Both types of cofactors leave long-lasting marks on histone tails, which eventually 
modifies the recruitment of type II polymerase and the transcription initiation rate or neighbor-
ing genes.
Although many progresses have been performed during the following 20 years, this canonical 
model still holds true. It is sufficient to explain most of the pleiotropic influence of T3 in physiology 
and development, and in the corresponding pathologies. However, a number of problems remain 
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to be solved, which are highlighted below. The choice is personal, 
and the goal is to stimulate new investigations.
THe ALLOSTeRiC PROPeRTieS OF THe 
TR/RXR/DR4/COACTivATOR COMPLeXeS 
AND THeiR PHARMACOLOGiCAL 
CONSeQUeNCeS
Studies of other nuclear receptors indicate that DNA-bound 
nuclear receptor dimers have allosteric properties, meaning that 
ligand binding, DNA binding, heterodimerization, and cofactor 
recruitment are interdependent processes and that local changes 
in receptor structure can influence distant domains of the pro-
tein. A systematic study of the estrogen receptors confirm that 
the DNA sequence of the response element, the type of receptor, 
the ligand, and involved coactivators all contribute to define the 
transactivation capacity of the complex in a highly unpredictable 
manner (5, 6). Structural analysis of the glucocorticoid receptor 
more precisely analyzed how changes in the nucleotide sequence 
of the hormone-response DNA element have broad consequences 
on dimer conformations, DNA-binding kinetics, and transcrip-
tional activity (7). Similarly, a single amino-acid substitution 
was found to deeply modify the repertoire of target genes (8). 
Structural analyses suggest that such long-distance allosteric 
effects also take place within TRs (9). For example, mutations in 
the C-terminal helix, located far from the ligand-binding pocket 
can reduce the affinity for T3 binding (10). Allostery also explains 
why some RXR-containing heterodimers are “permissive” for 
RXR, meaning that they can be activated by RXR agonists, while 
others are not (11, 12). RXR/TR heterodimers are thought to be 
always non-permissive for RXR, but one recent study suggests 
that there may be exceptions, in specific cellular contexts (13, 14). 
Therefore, a number of parameters, which are often overlooked, 
interplay to decide whether the recruitment of polymerase II 
and the transactivation of the neighboring gene will occur: exact 
sequence of the DNA-binding site and neighboring nucleotides, 
TR isotype, RXR isotype, and ligand.
This conclusion is important for the development of new 
TR ligands. Such synthetic compounds have been synthesized 
to develop thyromimetic drugs, which are expected to provide 
the beneficial effects of T3, notably cholesterol lowering, without 
having its cardiac toxicity. In addition to pharmacodynamics 
parameters, which, for example, tend to favor accumulation in 
hepatocytes, the allosteric influence of ligand binding may have 
important consequences on the receptor function (9). This has 
been elegantly exploited to synthesize a molecule able to activate 
an otherwise inactive mutant TRβ1 (15). Allosteric properties 
of TR/RXR/DR4 complexes might also be relevant for studies 
of thyroid hormone disruptors, as some of these environmental 
chemicals are thought to be TR ligands (16). Allostery also raises 
the intriguing possibility that thyroxine (T4), usually only consid-
ered as an inactive precursor of T3, and other natural iodinated 
compounds with different affinities for TRs (17), could trigger 
a distinct cellular response. Understanding allosteric properties 
of complexes would benefit from the resolution of the complete 
structure of the DNA-bound heterodimers, a very difficult task, 
which has only been achieved for PPAR/RXR, LXR/RXR, and 
VDR/RXR for the moment.
GeNOMe-wiDe STUDieS OPeN A  
wiDe FieLD OF iNveSTiGATiON
The advent of deep DNA sequencing allowed transposing a 
number of molecular biology assays at genome-wide scale. 
This deluge of datasets is not only broadening our view but also 
questioning textbook knowledge on gene expression. For exam-
ple, the distinction between promoters and enhancers is now 
uncertain (18). It also appears that enhancers are transcribed 
on both strands, as is a large fraction of the genome (19). In 
several cell types, it is now visible that transcription initiation is 
not necessarily the rate-limiting step of gene expression, due to 
the presence of a poised polymerase II (20). All these novelties 
have not yet been integrated in the molecular models of nuclear 
receptors function and will certainly influence our view on their 
mode of action.
In the field of T3 signaling, RNAseq, replacing microarray 
analysis, already produced a number of heat maps and lists of 
genes, from which it is difficult to extract a unifying picture for 
the moment (21). Taken together, these data confirm that different 
cell types respond to T3 in very different manners. Whether the 
gene induction is directly mediated by TR, or rather secondary 
to the rapid induction of another gene encoding an intermediate 
transcription factor, cannot be easily inferred from transcriptome 
analyses. Using an inhibitor of mRNA translation indicates that 
such secondary response starts within few hours after T3 stimu-
lation and that only a minority of the reported T3-responsive 
genes are directly regulated by TRs (22). Chromatin occupancy 
can be assayed at genome-wide scale (ChIPseq) to identify all 
TR-binding sites (the TR “cistrome”) present next to TR respon-
sive genes and better identify TR target genes. Three such studies 
mapped the sequence responsible for the T3 response of neural 
cells and hepatocytes (23–25). Two of these studies relied on 
tagging the N-terminus of TRs, to circumvent the difficulty of 
using antibodies raised against TR, which were thought to be of 
insufficient quality. However, the extensive overlap between the 
results later obtained with a commercially available antibody is 
reinsuring. This is clearly just a beginning, but these ChIPseq data 
brought a number of new questions.
ChIPseq analyses indicate that DR4 elements are predominant 
over other types of T3 response elements. While DR4-like elements 
are very frequent in the genome (>70 000), only a small subset is 
occupied in a given cell type. For other nuclear receptors, this type 
of situation is thought to result from the existence of “pioneer” 
factors required to open closed chromatin before nuclear receptor 
binding (26). However, there is no indication that such pioneer 
factors exist for TR binding. Furthermore, TRs seem able to create 
localized “open chromatin” structures after ligand binding (24). 
The significant overlap between the cistromes of hepatocytes and 
neural cells is in line with the possibility that chromatin compac-
tion is not the determinant for DR4 choice. This overlap contrasts 
with striking differences in chromatin opening in these cell types, 
as judged by DNaseI hypersensitivity (21). The occupancy of only 
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a small fraction of the DR4 elements present in the genome is thus 
unexplained for the moment.
Another surprise is the limited correlation that is observed 
between the occupation of a DR4 by TR and the transactivation 
of the neighboring gene after T3 treatment. Also, more than half 
of the rapidly responding genes possess a TR-occupied site within 
20 kb of the transcription start site, TR binding is only observed 
at very long distance (>50  kb) for a number of T3-responsive 
genes. Such long-distance regulation could be explained by 
chromatin looping, which brings distant sequences at vicinity 
(27). Reciprocally, and more surprisingly, a number of expressed 
genes with a proximal DR4 occupied by TR do not respond to 
T3. This fact is not understood, and outlines the need to better 
understand genome compartmentation, as insulating structures 
could define the distance at which TR can transactivate. Again, 
the possibility exists that the allosteric properties of the TR/RXR/
DR4 complexes define their transactivation capacity. This could 
explain why, in the same cells, genes can display a marked prefer-
ence for TRα1 or TRβ1, as this preference is not correlated with 
differential chromatin binding of the receptors (23).
Genome-wide scale data also indicate a very significant over-
lap between the cistrome of different nuclear receptors within 
the same cell type. ChIPseq data in mouse liver are available not 
only for TR but also for several other nuclear receptors, includ-
ing LXR, PPARα, PXR, and RXR (28, 29). As the physiological 
functions of the respective ligands of these receptors are clearly 
different, the extensive overlap between the cistromes is surpris-
ing. However, LXR/RXR, PXR/RXR, RXR/RXR, and RXR/TR 
dimers can all bind in  vitro to DR4 elements and apparently 
recruit the same types of transcription cofactors. In this respect, 
it is also puzzling that the overlap is not complete for these 
receptors. This situation entails that a number of genes should 
be equally activated by these receptors and that these nuclear 
receptors should cross-talk. TRβ1 does not leave any “footprint” 
on DNA (24) confirming a very unstable association with DNA 
and transient occupancy (30). If the binding of the other het-
erodimers is also labile, one should expect that the interaction 
between the pathways will not be competitive, but additive or 
synergetic. Furthermore, the existence of composite elements 
with more than two half-sites and the presence in nuclei of very 
large protein complexes containing several nuclear receptors 
(31) suggest a number of additional possibilities for cross-talks 
with the other nuclear receptors, which do not bind on DR4. Few 
examples have been already studied (32).
Transcriptome analyses in liver and brain cells indicate that 
genes can be either up- or downregulated after T3 stimulation. 
In pituitary-derived cells, in which the direct negative influence 
of TRβ1 on Thsb gene promoter is well documented, there is 
strong evidence that TRβ1 can be recruited to chromatin and 
bind Thsb gene regulatory sequences (33). Therefore, it seems that 
some unknown molecular mechanism can turn liganded TRβ1 
into a transcription repressor. What is the underlying molecular 
mechanism for T3-mediated transcriptional repression is cur-
rently unclear. Assuming that the mechanism is not peculiar to 
pituitary thyrotropic cells and might involve an unusual asso-
ciation of TRβ1 to chromatin at specific loci, ChIPseq data were 
thus eagerly expected. A global analysis revealed, however, that, 
at least in hepatocytes and neural cells, the genes which expres-
sion is negatively regulated after T3 stimulation do not usually 
possess a proximal-binding site occupied by TR. The most likely 
explanation is that the observed decrease in mRNA level, which 
becomes measurable only several hours after T3 treatment, is 
an indirect consequence of a rapid response to T3, for example, 
the induction of a gene encoding a transcription repressor. This 
is, however, a temporary conclusion, as a more direct analysis 
of transcription initiation has not been performed. Analyses of 
nascent RNA and of chromatin occupancy by RNA polymerase 
II are feasible at genome-wide scale and would bring a direct view 
of the transcriptional machinery.
GOiNG BeYOND THe  
CANONiCAL PATHwAY
An abundant and controversial literature reports that T3 
stimulates the generation of second messengers such as Ca2+, 
NO, inositol trisphosphate, and cAMP in various cells, in a rapid 
manner, which is incompatible with a transcriptional response 
(34). The changes influence the Akt and PKC signaling pathways, 
which eventually lead to a modification of gene expression (35). 
These rapid pathways are called “non-genomic,” although this 
designation can be confusing, because on the long term, they 
must eventually influence genome expression. Furthermore, as 
neurons without TR do not display any residual transcriptional 
response to T3 (22), the non-genomic response, at least in this cell 
population, probably involves proteins encoded by THRA and/
or THRB. This also suggests that the genomic and non-genomic 
responses are not entirely independent pathways.
Three of the proposed pathways for non-genomic signaling 
are compatible with an intervention of THRA- and THRB-
encoded proteins. Two of them involve the 30 and 43-kDa 
proteins encoded by THRA, both produced by alternate transla-
tion of TRα1 mRNA initiation in a number of cell types. The 
30-kDa, corresponding to the isolated ligand-binding domain, 
has been found to be at the plasma membrane, where it stimu-
lates Akt pathway (36). This is discordant with an older study 
claiming that the full-length TRα1 was activating this pathway in 
endothelial cells (37). By contrast, the 43-kDa protein has been 
detected by Western blotting in purified mitochondria (38). It 
still possesses the ability to bind DNA and has been proposed 
to act as a regulator of mitochondrial genome expression (39). 
Importantly, transgenic mice with selective elimination or 
overproduction of the 43-kDa protein have been produced, with 
significant developmental and physiological consequences (40, 
41). Another study (42) concluded that a fraction of the full-
length TRβ1 is also present at the plasma membrane. Unlike 
TRα1, which lacks a critical tyrosine residue, TRβ1 can serve 
as an intermediate between tyrosine kinase receptors and the 
PI3K/Akt pathway. Here again, this claim is supported by genetic 
evidence in mice (42, 43). Although self-consistent, all these 
studies lead to conclusions that are clearly not compatible, and 
it is likely that some of the proposed mechanisms will not resist 
deeper investigations. Settling this controversy would be easier if 
only few relevant cellular models were chosen and if the authors 
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could demonstrate the presence of THRA- or THRB-encoded 
proteins without using artificial overexpression. This last point 
is critical, and technically challenging, as the proteins abundance 
is generally very low, even in the nucleus. The molecular details 
explaining the subcellular localization and activity of all these 
proteins and others THRA products that are not mentioned here 
(44) remain in any case to be understood. Future investigations 
should also clarify how and why vertebrate evolution generated 
such a complexity.
CONCLUSiON
Despite its well-recognized weaknesses, the canonical model 
resisted well over the last decades. Recent technological progresses 
bring the promise that we will soon reach a deeper and broader 
understanding of thyroid hormone mode of action. As the hor-
mone fulfills many different functions, this would have important 
consequences in a number of different scientific fields.
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